Protocol Ledger

NCT06712316 · Phase II/III · RECRUITING

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Interventional Phase II/III clinical trial protocol NCT06712316 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-07 Enrollment: 1,580 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06712316
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,580 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06712316
Protocol FieldVerified Registry Value
NCT IdentifierNCT06712316
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,580 participants (ESTIMATED)
Registered Start Date2025-01-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06712316
Hospital Research SiteLocationSite Profile
Alaska Oncology and Hematology LLCAnchorage, AKOpen Hospital Dossier ->
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Cleveland Clinic FloridaWeston, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI